INTRODUCTION: Further understanding of adverse clinical events in patients with chronic kidney disease (CKD) is needed. This study aimed to describe characteristics of patients with nondialysis-dependent (NDD) and dialysis-dependent (DD) CKD and to assess incidence rates of uncommon adverse clinical events of interest in these patients. METHODS: This retrospective study used electronic medical record data from USA CKD patients (≥18 years) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 between January 1, 2010, and December 31, 2018, obtained from the USA-based TriNetX database. NDD-CKD and DD-CKD were diagnosed and staged from ≥2 consecutive eGFR readings, recorded ≥90 days apart. Dialysis was identified using procedure codes for renal replacement therapy. Outcomes assessed were select uncommon adverse clinical events, defined by International Classification of Disease, 9th and 10th Revision codes. RESULTS: Incidence rates of adverse clinical events per 100 person-years (95% confidence interval) were generally higher in patients with DD-CKD versus NDD-CKD. Differences were particularly pronounced for hyperkalemia (26.9 [26.2-27.6] vs. 4.5 [4.5-4.6]), acidosis (15.1 [14.7-15.6] vs. 3.4 [3.4-3.4]), and sepsis (14.6 [14.2-15.1] vs. 3.3 [3.3-3.4]). Among DD-CKD patients, incidence rates of adverse events were particularly high during the first 3 months following dialysis initiation. Incidence of adverse clinical events generally increased with decreasing eGFR among patients with NDD-CKD and with hemoglobin <10 g/dL in both NDD- and DD-CKD patients. CONCLUSIONS: Our results help establish baseline rates of uncommon adverse clinical events and provide additional evidence of increased morbidity for patients with DD-CKD versus NDD-CKD. The Author(s). Published by S. Karger AG, Basel.
INTRODUCTION: Further understanding of adverse clinical events in patients with chronic kidney disease (CKD) is needed. This study aimed to describe characteristics of patients with nondialysis-dependent (NDD) and dialysis-dependent (DD) CKD and to assess incidence rates of uncommon adverse clinical events of interest in these patients. METHODS: This retrospective study used electronic medical record data from USA CKD patients (≥18 years) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 between January 1, 2010, and December 31, 2018, obtained from the USA-based TriNetX database. NDD-CKD and DD-CKD were diagnosed and staged from ≥2 consecutive eGFR readings, recorded ≥90 days apart. Dialysis was identified using procedure codes for renal replacement therapy. Outcomes assessed were select uncommon adverse clinical events, defined by International Classification of Disease, 9th and 10th Revision codes. RESULTS: Incidence rates of adverse clinical events per 100 person-years (95% confidence interval) were generally higher in patients with DD-CKD versus NDD-CKD. Differences were particularly pronounced for hyperkalemia (26.9 [26.2-27.6] vs. 4.5 [4.5-4.6]), acidosis (15.1 [14.7-15.6] vs. 3.4 [3.4-3.4]), and sepsis (14.6 [14.2-15.1] vs. 3.3 [3.3-3.4]). Among DD-CKD patients, incidence rates of adverse events were particularly high during the first 3 months following dialysis initiation. Incidence of adverse clinical events generally increased with decreasing eGFR among patients with NDD-CKD and with hemoglobin <10 g/dL in both NDD- and DD-CKD patients. CONCLUSIONS: Our results help establish baseline rates of uncommon adverse clinical events and provide additional evidence of increased morbidity for patients with DD-CKD versus NDD-CKD. The Author(s). Published by S. Karger AG, Basel.
Authors: Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort Journal: Lancet Date: 2010-05-17 Impact factor: 79.321
Authors: Marcello Tonelli; Natasha Wiebe; Matthew T James; Scott W Klarenbach; Braden J Manns; Pietro Ravani; Giovanni F M Strippoli; Brenda R Hemmelgarn Journal: Kidney Int Date: 2018-03-07 Impact factor: 10.612
Authors: Jula K Inrig; Robert M Califf; Asba Tasneem; Radha K Vegunta; Christopher Molina; John W Stanifer; Karen Chiswell; Uptal D Patel Journal: Am J Kidney Dis Date: 2013-12-06 Impact factor: 8.860
Authors: Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs Journal: PLoS One Date: 2016-07-06 Impact factor: 3.240
Authors: Jennifer S Lees; Claire E Welsh; Carlos A Celis-Morales; Daniel Mackay; James Lewsey; Stuart R Gray; Donald M Lyall; John G Cleland; Jason M R Gill; Pardeep S Jhund; Jill Pell; Naveed Sattar; Paul Welsh; Patrick B Mark Journal: Nat Med Date: 2019-11-07 Impact factor: 53.440
Authors: Simon D S Fraser; Paul J Roderick; Carl R May; Natasha McIntyre; Christopher McIntyre; Richard J Fluck; Adam Shardlow; Maarten W Taal Journal: BMC Nephrol Date: 2015-12-01 Impact factor: 2.388
Authors: Gunnar Toft; Uffe Heide-Jørgensen; Heleen van Haalen; Glen James; Katarina Hedman; Henrik Birn; Christian F Christiansen; Reimar W Thomsen Journal: J Nephrol Date: 2019-10-05 Impact factor: 3.902
Authors: Glen James; Juan Jose Garcia Sanchez; Juan Jesus Carrero; Supriya Kumar; Roberto Pecoits-Filho; Hiddo J L Heerspink; Stephen Nolan; Carolyn S P Lam; Hungta Chen; Eiichiro Kanda; Naoki Kashihara; Matthew Arnold; Mikhail N Kosiborod; Mitja Lainscak; Carol Pollock; David C Wheeler Journal: Kidney Int Rep Date: 2022-06-08